Sanofi has asked bidders to revise their proposals for its Opella business in the coming days, Ruth David, Dinesh Nair and Pamela Barbaglia of Bloomberg report, citing people with knowledge of the matter. The request gives bidders the chance to either improve their proposals or provide additional clarity on specific terms under negotiation, sources told Bloomberg. A deal could value the unit around $16.6B people, the people added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Regeneron, Sanofi announce Dupixent approved in U.S. for COPD patients
- Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
- Biotech Alert: Searches spiking for these stocks today
- Amgen data from rocatinlimab in AD ‘look unimpressive,’ says Baird
- Sanofi’s Tolebrutinib Delays MS Disability Progression